Reply to Comments From Dr Lozano, et al--Concerning the Prevalence of Lithium-Associated Hyperparathyroidism

Affiliations

¹ Department of Geriatrics, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.Psychiatric Research Centre, Örebro University, Örebro, Sweden.Department of Psychiatry, Ryhov Hospital, Jönköping, Sweden.Department of Surgery, Ryhov Hospital, Jönköping, Sweden.Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Comment

Adrian David Meehan et al. J Clin Psychopharmacol. 2016 Apr.

. 2016 Apr;36(2):191-2.

doi: 10.1097/JCP.0000000000000477.

¹ Department of Geriatrics, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.Psychiatric Research Centre, Örebro University, Örebro, Sweden.Department of Psychiatry, Ryhov Hospital, Jönköping, Sweden.Department of Surgery, Ryhov Hospital, Jönköping, Sweden.Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

No abstract available

Comment on

The prevalence of lithium-associated hyperparathyroidism in a large Swedish population attending psychiatric outpatient units.
Meehan AD, Humble MB, Yazarloo P, Järhult J, Wallin G. Meehan AD, et al. J Clin Psychopharmacol. 2015 Jun;35(3):279-85. doi: 10.1097/JCP.0000000000000303. J Clin Psychopharmacol. 2015. PMID: 25853371
Sustained Hyperparathyroidism Among Patients Treated With Lithium.
Lozano R, Marin R, Santacruz MJ, Pascual A. Lozano R, et al. J Clin Psychopharmacol. 2016 Apr;36(2):190-1. doi: 10.1097/JCP.0000000000000473. J Clin Psychopharmacol. 2016. PMID: 26848789 No abstract available.